Clinical Trial Update: Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of the BET inhibitor PLX51107 for steroid-refractory acute graft-versus-host disease was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Steroid-refractory Graft-versus-host Disease

Drugs mentioned

• PLX51107

Snippet

Sponsor: Hannah Choe, MD | Conditions: Acute Graft Versus Host Disease, Steroid Refractory Graft Versus Host Disease | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-01-28